Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis

Digestive Diseases

Volumn 32, Issue 3, 2014, Pages 265-274

  Pizzi, Marco ^a   Saraggi, Deborah ^a   Fassan, Matteo ^b   Megraud, Francis ^d   Di Mario, Francesco ^c   Rugge, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Atrophic gastritis; Gastric cancer; Helicobacter pylori; OLGA staging system

Indexed keywords

ARTICLE; ATROPHIC GASTRITIS; CANCER EPIDEMIOLOGY; CANCER STAGING; GASTRIC MUCOSA ATROPHY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HISTORY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SECONDARY PREVENTION; STOMACH ATROPHY; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; BIOLOGICAL MODEL; BLOOD; CARCINOGENESIS; COMPLICATION; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; STOMACH NEOPLASMS; ATROPHY; CANCER PREVENTION; CANCER RISK; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; MUCOSA ATROPHY; MUCOSAL DISEASE; SEROLOGY;

CARCINOGENESIS; GASTRITIS; HELICOBACTER PYLORI; HUMANS; MODELS, BIOLOGICAL; SECONDARY PREVENTION; STOMACH NEOPLASMS;

EID: 84898906990     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000357857     Document Type: Article

References (64)

1. Calvet X, Ramírez Lázaro MJ, Lehours P, et al: Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 2013; 18(suppl 1):5-11.
2. Brown LM: Helicobacter pylori : Epidemiology and routes of transmission. Epidemiol Rev 2000; 22: 283-297.
3. Correa P: The biological model of gastric carcinogenesis. IARC Sci Publ 2004; 157: 301-310.
4. Rugge M, Capelle LG, Cappellesso R, et al: Precancerous lesions in the stomach: From biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013; 27: 205-223.
5. Rugge M, Fassan M, Graham DY: Clinical guidelines: Secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol 2012; 9: 128-129.
6. Owen DA: Stomach; in Mills SE (ed): Histology for Pathologists, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 589-602.
7. Khurana S, Mills JC: The gastric mucosa development and differentiation. Prog Mol Biol Transl Sci 2010; 96: 93-115.
8. Jass JR, Filipe MI: The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981; 13: 9231-9239.
9. Chu S, Schubert ML: Gastric secretion. Curr Opin Gastroenterol 2012; 28: 587-593.
10. Qiao XT, Gumucio DL: Current molecular markers for gastric progenitor cells and gastric cancer stem cells. J Gastroenterol 2011; 46: 855-865.
11. Han ME, Oh SO: Gastric stem cells and gastric cancer stem cells. Anat Cell Biol 2013; 46: 8-18.
12. Miller ML, Andringa A, Zavros Y, et al: Volume density, distribution, and ultrastructure of secretory and basolateral membranes and mitochondria predict parietal cell secretory (dys)function. J Biomed Biotechnol 2010; 2010: 394198.
13. Madsen KM, Tisher CC: Structure-function relationships in H+-secreting epithelia. Fed Proc 1985; 44: 2704-2709.
14. Gritti I, Banfi G, Roi GS: Pepsinogens: Physiology, pharmacology pathophysiology and exercise. Pharmacol Res 2000; 41: 265-281.
15. Samloff IM: Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971; 61: 185-188.
16. Samloff IM, Liebman WM: Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973; 65: 36-42.
17. Rugge M, Genta RM: Staging and grading of chronic gastritis. Hum Pathol 2005; 36: 228-233.
18. Rugge M, Pennelli G, Pilozzi E, et al: Gastritis: The histology report. Dig Liver Dis 2011; 43(suppl 4):S373-S384.
19. Ferreri AJ, Govi S, Ponzoni M: Marginal zone lymphomas and infectious agents. Semin Cancer Biol 2013; 23: 431-440.
20. Wu TT, Hamilton SR: Lymphocytic gastritis: Association with etiology and topology. Am J Surg Pathol 1999; 23: 153-158.
21. Kimura K, Satoh K, Ido K, et al: Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl 1996; 214: 17-20.
22. Correa P, Piazuelo MB: Natural history of Helicobacter pylori infection. Dig Liver Dis 2008; 40: 490-496.
23. Uemura N, Okamoto S, Yamamoto S: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
24. Rugge M, Correa P, Dixon MF, et al: Gastric mucosal atrophy: Interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 1249-1259.
25. Ruiz B, Garay J, Correa P, et al: Morphometric evaluation of gastric antral atrophy: Improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001; 96: 3281-3287.
26. Rugge M, Meggio A, Pennelli G, et al: Gastritis staging in clinical practice: The OLGA staging system. Gut 2007; 56: 631-636.
27. Genta RM: Differential diagnosis of reactive gastropathy. Semin Diagn Pathol 2005; 22: 273-283.
28. Weis VG, Goldenring JR: Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 2009; 12: 189-197.
29. Nam KT, Lee HJ, Sousa JF, et al: Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology 2010; 139: 2028-2037.
30. Correa P, Piazuelo MB, Wilson KT: Pathology of gastric intestinal metaplasia: Clinical implications. Am J Gastroenterol 2010; 105: 493-498.
31. Matsukura N, Suzuki K, Kawachi T, et al: Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980; 65: 231-240.
32. Filipe MI, Munoz N, Matko I, et al: Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia. Int J Cancer 1994; 57: 324-329.
33. Jass JR, Filipe MI: Sulphomucins and precancerous lesions of the human stomach. Histopathology 1980; 4: 271-279.
34. LeungWK, Sung JJY: Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002; 16: 1209-1216.
35. Gutierrez-Gonzalez L, Wright NA: Biology of intestinal metaplasia in 2008: More than a simple phenotypic alteration. Dig Liver Dis 2008; 40: 510-522.
36. Silva E, Teixeira A, David L, et al: Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Arch 2002; 440: 311-317.
37. Piazuelo MB, Haque S, Delgado A, et al: Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 2004; 17: 62-74.
38. Vannella L, Lahner E, Osborn J, et al: Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010; 31: 1042-1050.
39. Morson BC, Sobin LH, Grundmann E, et al: Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol 1980; 33: 711-721.
40. Lauwers GY, Riddell RH: Gastric epithelial dysplasia. Gut 1999; 45: 784-790.
41. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, International Agency for Research on Cancer, 2010.
42. Rugge M, Correa P, Dixon MF, et al: Gastric dysplasia: The Padova international classification. Am J Surg Pathol 2000; 24: 167-176.
43. Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255.
44. Fassan M, Pizzi M, Farinati F, et al: Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. Am J Clin Pathol 2012; 137: 727-732.
45. Miehlke S, Hackelsberger A, Meining A, et al: Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori . Br J Cancer 1998; 78: 263-266.
46. Cassaro M, Rugge M, Gutierrez O, et al: Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95: 1431-1438.
47. Genta RM, Rugge M: Assessing risks for gastric cancer: New tools for pathologists. World J Gastroenterol 2006; 12: 5622-5627.
48. Rugge M, Genta RM, OLGA-Group: Staging gastritis: An international proposal. Gastroenterology 2005; 129: 1807-1808.
49. Dixon MF, Genta RM, Yardley JH, et al: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.
50. Rugge M, Correa P, Di Mario F, et al: OLGA staging for gastritis: A tutorial. Dig Liver Dis 2008; 40: 650-658.
51. Kodama M, Murakami K, Okimoto T, et al: Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol 2013; 48: 1249-1256.
52. Rugge M, de Boni M, Pennelli G, et al: Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104-1111.
53. Rugge M, Kim JG, Mahachai V, et al: OLGA gastritis staging in young adults and countryspecific gastric cancer risk. Int J Surg Pathol 2008; 16: 150-154.
54. Rugge M, Fassan M, Pizzi M, et al: Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol 2011; 42: 1539-1544.
55. Capelle LG, de Vries AC, Haringsma J, et al: The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-1158.
56. Rugge M, Fassan M, Pizzi M, et al: Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011; 17: 4596-4601.
57. Agréus L, Kuipers EJ, Kupcinskas L, et al: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012; 47: 136-147.
58. Miki K, Fujishiro M, Kodashima S, et al: Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009; 21: 78-81.
59. Sipponen P, Ranta P, Helske T, et al: Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: An observational casecontrol study. Scand J Gastroenterol 2002; 37: 785-791.
60. Kikuchi R, Abe Y, Iijima K, et al: Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with highrisk of early gastric cancer. Tohoku J Exp Med 2011; 223: 35-44.
61. Väänänen H, Vauhkonen M, Helske T, et al: Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: A multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-891.
62. Storskrubb T, Aro P, Ronkainen J, Sipponen P, et al: Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol 2008; 43: 1448-1455.
63. Di Mario F, Cavallaro LG, Moussa AM, et al: Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: Relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci 2006; 51: 1791-1795.
64. de Martel C, Forman D, Plummer M: Gastric cancer: Epidemiology and risk factors. Gastroenterol Clin North Am 2013; 42: 219-240.